Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 1979;7(3):119-27.
doi: 10.1007/BF01641311.

[Experience with sisomicin in pediatrics (author's transl)]

[Article in German]

[Experience with sisomicin in pediatrics (author's transl)]

[Article in German]
L Weingärtner et al. Infection. 1979.

Abstract

Sisomicin, an aminoglycoside antibiotic, is especially effective against Escherichia coli, Klebsiella, Enterobacter, Citrobacter, Serratia, indole-positive and indole-negative Proteus species, Pseudomonas aeruginosa, Salmonella and Staphylococcus aureus. It has a bactericidal action. Although sisomicin is similar to the other aminoglycoside antibiotics, there is not complete cross-resistance to them. Our own pharmacokinetic investigations showed that a dose of 2--3 mg/kg body weight of sisomicin twice daily is necessary in the neonatal period. Infants should be given 2.5 mg/kg body weight three times daily, and school children 1.5--20 mg/kg body weight, likewise three times daily. Excretion of sisomicin in the urine is lower in children than in adults, amounting within 24 hours to only 10--20% in newborns, and 30--40% in school-children. Sisomicin induces excretion of some enzymes in higher quantities from the tubular part of the kidneys, especially alaninaminopeptidase. A report is given on 58 patients, especially newborns and prematures, who were treated for about seven days with sisomicin. The results obtained with a wide variety of infections (such as omphalitis, aspiration of amniotic fluid with broncho-pneumonia, phlegmons of the galea, and also pyelonephritis and mucoviscidosis with pulmonary complications) can be described as good, with a success rate of 85%. On only seven occasions were insignificant transitory side-effects, such as slight increase in transaminases, toxic-allergic exanthema and pain in the region in injection, observed.

PubMed Disclaimer

Similar articles

References

    1. Am J Dis Child. 1973 Oct;126(4):473-7 - PubMed
    1. Antimicrob Agents Chemother. 1973 Dec;4(6):617-25 - PubMed
    1. Antimicrob Agents Chemother. 1973 Jan;3(1):24-8 - PubMed
    1. Z Med Lab Diagn. 1977 Jun;18(3):190-212 - PubMed
    1. J Chromatogr. 1969 Mar 25;40(2):254-63 - PubMed

Publication types